Essential Dynamic Transformation as Specific Highly Characterizable Indices of Progression of the Initial Mild Cognitive Impairment Phase of Alzheimer Patients

Lawrence M Agius*
Department of Pathology, University of Malta Medical School, Malta Europe

*Corresponding author: Lawrence M Agius, Department of Pathology, Mater Dei Hospital, Tal-Qroqq, University of Malta Medical School, Msida, Malta Europe, Tel: 356-21451752; E-mail: lawrence.agius@um.edu.mt

Abstract
Dynamics of transforming potential underlie the systems of heterogeneous progression to a final demented state in Alzheimer patients. Such dynamics reflect many of the attributes of an essentially variable vascular series of substrates that implicate various component systems of the blood brain barrier as endothelium and also of the subcortical structures and cortex as further delineated by systems of heterogeneous nature in progression of the mild cognitive impairment of Alzheimer type. Transforming dynamics of initial mild phases of cognitive impairment come to assume a dominant profile determination that characterises the subsequent emergence of neuronal lesions and of neuronal cell loss as suggested by development of synaptic pathology and as further projected by the development of neuritic plaques and neurofibrillar tangles. Amyloid-beta is a recognizable feature of Alzheimer pathology that evolves as accumulative dimensions of such Alzheimer pathology.

Keywords: Mild Cognitive; Clinical dementia; Alzheimer’s disease

Introduction
Alzheimer’s disease constitutes the commonest cause of clinical dementia, followed by a category of vascular dementia that is increasingly being recognized both clinically and pathologically. The global brain involvement particularly concerns the subcortical white matter in cases of arteriosclerotic and capillary cases of dementia. Impaired brain glucose metabolism precedes onset of Alzheimer’s disease and this might possibly be compensated for by a ketogenic intervention, as perhaps suggested by a cross-sectional study [1]. Also, plasma total tau levels are associated with cognition decline and is independent of elevated brain Amyloid-beta [2].

Tissue/organ substrate involvement in Alzheimer’s disease is a structurally driven group of heterogeneous conditions that is increasingly augmented by vascular involvement to the central nervous system, as indicated by the emergent risk for dementia in patients who suffer an initial stroke episode. Breakdown of the blood brain barrier may promote cognitive decline [3]. It has
generally been suggested that structural involvement with atrophy of the medial temporal lobe structures and the para-limbic atrophy in patients with dementia indicate a selective involvement by Alzheimer’s disease [4,5].

Platelets may be involved in Amyloid-beta plaque processing and operate within contexts of cerebral amyloid angiopathy, tau pathology, and inflammation [6]. However, consequent forms of involvement as defined in terms of brain regions are more related to amnestic syndromes and a loss of executive function as seen more classically with vascular causes of dementia [7]. While short-term longitudinal assessments improve performance of Alzheimer disease prediction models episodic memory assessment has, however, traditionally been used to evaluate potential cognitive impairments in older adults [8,9].

Dynamics

Dynamics of subcortical micro-infarcts are perhaps better regarded as tissue substrate for brain atrophy and of neuronal cell loss that progresses in terms of the accelerated phase of leukariaiosis and apoptosis of oligodendrocytes on the one hand and of perivascular lacunae and arteriosclerotic abnormalities inducing secondary effects of hypertension, type II diabetes mellitus and other vascular pathology. The parameters of involvement of the cortex as multifocal involvement of a global brain pathology is an apparent distinction to the variably progressive white matter ischemia and infarction in patients especially with vascular dementia. Brain glucose metabolism and amyloid load are extremely powerful in diagnosis and prognosis as biomarkers that predict mild cognitive impairment to Alzheimer disease conversion [10].

The described neuropathological features that dominate the brain involvement in Alzheimer’s disease is a process of progression from an initial phase of mild cognitive impairment and is reflected also in the mild vascular impairment leading to essential parameters of clinical and pathologic progression of multiple factorial agents. Both common and unique sets appear implicated in Alzheimer disease and aging, and may indicate distinct age-related differences in early compared to late aging [11].

A range of biomarkers indicates Alzheimer’s disease as an essential molecular, cellular and functional derangement that operates within structural indices of selective and also global brain atrophy especially revealed by structural magnetic resonance imaging. A frequency distribution-based index of functional connectivity may prove a good biomarker for Alzheimer’s disease across multiple sites and also be useful in mild cognitive impairment [12]. Brain functional connectivity extracted from resting-state fMRI (RS-fMRI) is popular in diagnosing neurodegenerative states and Alzheimer’s disease, including mild cognitive impairment [13]. Both cognitive tests and clinical dementia ratings can be combined across multiple studies to obtain a reliable algorithmic classification of mild cognitive impairment that is highly specific and sensitive [14].

Parameters of Vascular Involvement

A vascular basis for the majority of the lesions found in patients diagnosed with Alzheimer’s disease is much debated but the relative interactivities between small vessel or large vessel involvement and of the clinical state of otherwise classical Alzheimer’s disease are considerations arising from essential tissue/organ substrate specifications in clinically demented patients. Lower levels of nutrients involved in synaptic phospholipid synthesis may be found in early stages of Alzheimer’s disease [15].

Indeed, vascular pathology appears to follow a more variable course than amnestic Alzheimer patients and this is reflected by a whole spectrum of involved parameters as specifically recognized vascular risk factors.

Heterogeneity

The essential heterogeneity of Alzheimer patient substrate is reflected in the lack of final demented states that are induced in general terms by both genetic and acquired pathologic lesions as best exemplified also by clinically recognizable small vessel pathology of the brain and the white matter in particular. Personality traits also can alter vulnerability and pathoplasticity of disease in mild cognitive impairment [16].

A diffuse involvement and a multi-focal pathology appear to synergistically progress in terms of specific parametric indices. Wallerian degeneration of neurons and trans-synaptic pathology are substrate parameters that appear to underlie progression from the mild cognitive impairment phase to a diffuse and also multi-regional selectivity that characterises dynamics of the emerging demented state as seen and assessed clinically.

The vast implications of brain atrophy in Alzheimer’s disease diagnosed by various criteria including especially clinical parameters of progression indicate a relative
reference to such structural components as the endothelium of the blood brain barrier in further dynamic turnover of a varied accumulation of parameters. Also, salivary lactoferrin has been shown to permit early diagnosis of mild cognitive impairment and allow for early critical disease-modification or prevention [17].

The distinctive vascular risk factors include the apolipoprotein E 4 subtype that is genetically determined but that is targeted to the endothelial cells of microvessels as one selective substrate for dementia progression. Electroencephalography-derived measures of brain oscillatory activity relate to clinical progression in amyloid-positive non-demented subjects [18].

**Vascular Risk Factors**

A significant association with vascular risk factors such as hypertension and type II diabetes mellitus with clinical dementia arises within the aging process of the individual that is perhaps regarded as a heterogeneity of variable parameters such as white matter subcortical pathology of potentially global dimensions. Olfactory identification deficit predicts white matter tract impairment in both aging and Alzheimer's disease [19]. Olfactory abnormalities often precede cognitive symptoms in Alzheimer's disease [20].

The essential dynamics of a given early or preclinical phase of mild cognitive impairment or of an increasingly recognized mild vascular cognitive impairment emerge as the potential for progression of neuronal cell loss and of white matter and cortical atrophy of a brain involvement that transforms to global dimensions. Social cognitive deficits are more severe in multi-domain mild cognitive impairment, and a need exists to investigate this in the production and conversion to dementia [21].

**Progression**

Determinations of progression of Alzheimer dementia are thus related to progression of the vascular substrate in many demented patients as clinically diagnosed.

The spectrum of potential progression is a relative index of parameters that both transform and further specify the dynamics of a lesion that is focally targeted to neurons and also globally targeted to white matter and cortex of the brain. Ryanodine receptor dysfunction in Alzheimer disease involves receptor post-translational remodelling involving PKA phosphorylation, oxidation and nitrosylation; induced endoplasmic reticular calcium leak activates Ca\(^{2+}\)-dependent signaling pathways driving pathogenesis of the demented state [22].

The potential reversibility of vascular substrates for the demented state lies largely within the heterogeneous substrates of involvement of the cerebral blood supply as further illustrated by dynamics of ischemia and infarction particularly of the subcortical white matter in many instances. Interventions targeting early atherosclerosis of the carotid may modify cognitive aging in individuals with a higher risk for Alzheimer disease [23]. Progression relies on an essential transformation series of substrate manipulations that pathologically involve neuronal cell loss beyond a strict categorization of purely neurodegenerative mechanisms.

**Essential Transformation of Substrate**

Strict transformation of the progression from the initial mild cognitive impairment is the tissue/organ substrate selectivity of a global involvement of the Alzheimer brain and this also applies to a variable extent to patients who are afflicted by mild vascular cognitive impairment. Patients with chronic subsyndromal depression may constitute a subgroup of mild cognitive impairment that is highly prone to accelerated cognitive decline, with atrophy of the frontal lobe and anterior cingulate lobe [24]. Delineation of such transforming dynamics potentially implicates a specificity of substrate pathology that is both accumulative and progressive. Amino acids contribute to a characteristic metabotype during progression of Alzheimer disease and may help identify at-risk subjects [25]. The heterogeneity of dementia substrates reflects a specificity of involvement of neurons that is further projected as subsequent consequences of the neuronal loss. The blood brain barrier and the specific cerebral vasculature implicate a series of transforming indices that reflects dynamics of risk factors that are based primarily as vascular substrates for further transformation.

**From Transformation to Progression**

Identification of transforming substrates in the vasculature supply of the brain indicates dynamics beyond the concepts of strategic infarction or of multi-infarction. Indeed, the range of afflictions in Alzheimer patients presents fixed patterns of pathology that belie the essential heterogeneity of dementia that is pathologically progressive and end-stage in its dominant manifestations, both clinically and pathologically.

**Concluding Remarks**

Essential transformation of pathologic substrates in clinically demented patients is inherent to the range of dynamic transformation of the initial mild cognitive
impairment phase as noted clinically. The individualization of the vascular risk factors that specifically and dynamically accumulate and further transform to a progressively dementing state is a challenge that is reflected in accumulating dynamics of risk factors that characterize a relatively limited spectrum of neuronal pathologies within the paradoxically wide range of induced cortical and white matter substrates of progression.

References

1. Croteau E, Castellano CA, Fortier M, Bocti C, Fulop T, et al. (2017) A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer’s disease. Exp Gerontol pii: S0531-5565(17)30228-0.

2. Mielke MM, Hagen CE, Wennberg AMV, Airey DC, Savica R, et al. (2017) Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic study on aging. JAMA Neurol 74(9): 1073-1080.

3. Freeze WM, Schnerr RS, Palm WM, Jansen JF, Jacobs HI, et al. (2017) Pericortical enhancement on delayed post gadolinium fluid-attenuated inversion recovery images in normal aging, mild cognitive impairment, and Alzheimer disease. Am J Neuroradiol 38(9): 1742-1747.

4. De la Torre JC (2002) Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33(4): 1152-1162.

5. Cacabelos R, Fernández-Novoa L, Lombardi V, Corzo L, Pichel V, et al. (2003) Cerebrovascular risk factors in Alzheimer’s disease: brain hemodynamics and pharmacogenomic implications. Neurol Res 25(6): 567-580.

6. Humpeal C (2017) Platelets: their potential contribution to the generation of beta-amyloid plaques in Alzheimer’s disease. Curr Neurovasc Res 14(3): 290-298.

7. Chui HC (1989) Dementia. A review emphasizing clinicopathologic correlation and brain-behavior relationships. Arch Neurol 46(7): 806-814.

8. Mubeen AM, Asaee A, Bachman AH, Sfidis JJ, Ardekani BA, et al. (2017) A six-month longitudinal evaluation significantly improves accuracy of predicting incipient Alzheimer’s disease in mild cognitive impairment. J Neuroradiol 44(6): 381-387.

9. Valladares-Rodriguez S, Perez-Rodriguez R, Facal D, Fernandez-Iglesias MJ, Anido-Rifon L, et al. (2017) Design process and preliminary psychometric study of a video game to detect cognitive impairment in senior adults. Peer J 30(5): e3508.

10. Iaccarino L, Chiotis K, Alongi P, Almkvist O, Wall A, et al. (2017) A cross-validation of FDG- and Amyloid-PET biomarkers in mild cognitive impairment for the risk prediction to dementia due to Alzheimer’s disease in a clinical setting. J Alzheimer’s Dis 59(2): 603-614.

11. Doan NT, Engvig A, Zaske K, Persson K, Lund MJ, et al. (2017) A resting-state functional connectivity index identify patients with Alzheimer’s disease and mild cognitive impairment across multiple sites?. Brain Connect.

12. Chen X, Zhang H, Zhang L, Shen C, Lee SW, et al. (2017) Extraction of dynamic functional connectivity from brain grey matter and white matter for MCI classification. Hum Brain Mapp 38(10): 5019.

13. Gross AL, Hassenstab JJ, Johnson SC, Clark LR, Resnick SM, et al. (2017) A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: the preclinical AD consortium. Alzheimers Dement (Amst) 8: 147-155.

14. van Wijk N, Slot RER, Duits FH, Strik M, Biesheuvel E, et al. (2017) Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer’s disease dementia. Alzheimer’s Dement (Amst) 8: 139-146.

15. Zufferey V, Donati A, Popp J, Meuli R, Rossier J, et al. (2017) Neuroticism, depression, and anxiety traits exacerbate the state of cognitive impairment and hippocampal vulnerability to Alzheimer’s disease. Alzheimer’s Dement (Amst) 6: 107-114.

16. Caro E, Bartolome F, Bermejo-Pareja F, Villarreal-Galende A, Molina JA, et al. (2017) Early diagnosis of
mild cognitive impairment and Alzheimer’s disease based on salivary lactoferrin. Alzheimers Dement (Amst) 8: 131-138.

18. Gouw AA, Alsema AM, Tijms BM, Borta A, Scheltens P, et al. (2017) EEG spectral analysis as a putative early prognostic biomarker in non demented, amyloid positive subjects. Neurobiol Aging 57: 133-142.

19. Woodward MR, Dwyer MG, Bergsland N, Hagemeier J, Zivadinov R, et al. (2017) Olfactory identification deficit predicts white matter tract impairment in Alzheimer’s disease. Psychiatry Res 266: 90-95.

20. Hamodat H, Cash MK, Fisk JD, Dervish S (2017) Cholinesterases in normal and Alzheimer’s disease primary olfactory gyrus. Neuropathol Appl Neurobiol 43(7): 571-583.

21. Bora E, Yener GG (2017) Meta-Analysis of social cognition in mild cognitive impairment. J Geriatr Psychiatry Neural 30(4): 206-213.

22. Lacampagne A, Liu X, Reiken S, Bussiere R, Meli AC, et al. (2017) Post-translation remodelling of ryanodine receptor induces calcium leak leading to Alzheimer’s disease-like pathologies and cognitive deficits. Acta Neuropathol 134(5): 749-767.

23. Gardener H, Caunca MR, Dong C, Cheung YK, Eiking MSV, et al. (2017) Ultrasound markers of carotid atherosclerosis and cognition: the northern Manhattan study. Stroke 48(7): 1855-1861.

24. Gonzales MM, Insel PS, Nelson C, Tosun D, Mattsson N, et al. (2017) Cortical atrophy is associated with accelerated cognitive decline in mild cognitive impairment with subsyndromal depression. Am J Geriatr Psychiatry 25(9): 980-991.

25. Corso G, Cristofano A, Sapere N, la Marca G, Angiolillo A, et al. (2017) Serum amino acid profiles in normal subjects and in patients with or at risk of Alzheimer dementia. Dement Geriatr Cogn Dis Extra 7(1): 143-159.